This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Monday's Health Winners & Losers

Health indices lacked luster Monday, while a few biotech stocks kicked off the week with a swath of regulatory news.

GlaxoSmithKline (GSK - Get Report) said Monday that the Food and Drug Administration has more questions for the company regarding its cervical cancer vaccine Cervarix before the product can be approved.

The agency's Center for Biologics Evaluation and Research issued Glaxo a "complete response letter" to its Cervarix application, signaling that the review is complete but questions have to be answered before the drug can be approved. Glaxo said it will submit a response to the FDA letter on Cervarix, which is already approved in markets outside the U.S., as soon as possible.

Glaxo shares fell $1.05, or 2%, to $51.95. The stock is a component of the Amex pharmaceutical index, which was down 3.57, or 1%, to 344.25.

Meanwhile, the European Commission granted marketing authorization for Atripla, an HIV drug that was joint-filed by Bristol-Myers Squibb (BMY - Get Report), Genentech (DNA) and Merck (MRK - Get Report) for commercialization in the 27 countries of the E.U., as well as in Norway and Iceland. The drug has been approved in the U.S. since 2006. Bristol was up just 3 cents at $28.11, Genentech was down $1.32, or 2%, at $67.11, and Merck was up 8 cents, or 0.1%, to $59.65.

In other regulatory news, Medtronic (MDT - Get Report) said Monday that it received Japanese regulatory approval on Dec. 10 for its Sprint Quattro lead, a wire used with implantable cardioverter-defibrillators (ICDs) that detect and treat rapid and potentially lethal heart rhythms. The company said it hopes to receive reimbursement for the lead by Jan. 1, in which case it would immediately begin the commercial launch in Japan. In October, the company recalled its Fidelis leads, sparking a shift to the use of its Quattro leads, but Quattro lead product hadn't been approved in Japan. Medtronic shares were down 25 cents, or 0.5%, at $49.15.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BMY $65.00 0.46%
ENDP $87.81 -0.53%
GSK $46.66 -1.50%
MDT $76.61 -0.89%
MRK $57.60 -1.13%

Markets

DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs